# Immunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer.

> **NCT05116917** · PHASE2 · TERMINATED · sponsor: **Herlev Hospital** · enrollment: 19 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab
- **BIOLOGICAL:** Influenza vaccine
- **RADIATION:** SBRT

## Key facts

- **NCT ID:** NCT05116917
- **Lead sponsor:** Herlev Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-11-05
- **Primary completion:** 2023-10-19
- **Final completion:** 2023-10-19
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Based on the precpecified interim analysis the predictive probability was below 10% for the prespecified endpoint.
- **Last updated:** 2024-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05116917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05116917, "Immunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05116917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*